Skip to main content
Case Report

Expandable Sheath Perforation in Transcatheter Aortic Valve Replacement

    Bernadette Speiser, BSN, MSN, CCRN, RCIS; Xi Yuan, BSN, RCIS

    Palo Alto Health Care System, Department of Veteran’s Affairs, Palo Alto, California

    Editor's Note: A pdf is available for download at right (look for the red PDF icon).

July 2021

Introduction

Aortic stenosis has been treated with transcatheter aortic valve replacement (TAVR) since 2002 by Dr. Cribier and his colleagues.¹ The most common delivery technique for catheter-based valve replacement has been the retrograde femoral artery approach. Initially, access was achieved in the clinical arena via surgical cutdown. However, due to improvements in technology, reduction in sheath size, and large-bore catheter vascular closure devices (VCD), there has been accumulating evidence supporting the percutaneous approach’s superior safety and efficacy.²

Nakamura et al³ identified the feasibility of the complete percutaneous approach and included acceptable safety and clinical benefits. The percutaneous arm versus the surgical cut-down arm of their study identified a reduction in wound infections, reduction in hospital bed days of care, and fewer bleeding complications. However, the group also noted that while the incidence of vascular events was higher in the percutaneous group, it did not affect in-hospital mortality. The Spanish TAVI Registry also reported that the percutaneous approach bore higher rates of minor vascular complications but lower rates of major bleeding at 30 days and at mid-term follow-up.⁴ Iliofemoral vascular complications weren’t common for the percutaneous group. Aortic complications were rare (0.6-1.9%), but carried a high mortality rate.

Prior to the TAVR procedure, a computed tomography angiography (CTA) is utilized in part to help identify vascular access risks. The luminal diameter of the access vessels, presence of any dissections, height of bifurcation vessels, and calcium burden are essential to evaluate and ensure a successful percutaneous approach. For the 26 mm Sapien 3 Ultra valve (Edwards Lifesciences), the product literature states the requirement of a minimum diameter of 5.5 mm for the 14 French delivery system.

During access, utilization of ultrasound guidance as well as fluoroscopic imaging should be implemented to compare specific landmarks. Use of the common femoral artery CTA  in comparison to the femoral head on fluoroscopy will provide further delineation of access entry.

Please Log In To View
Lorem ipsum dolor sit amet consectetur adipiscing elit augue, accumsan proin eros arcu quam eu finibus quis, porta sollicitudin mollis condimentum cras consequat nascetur. Velit vitae aptent odio iaculis per libero natoque cubilia est suspendisse, cras aliquam dapibus tortor mi morbi sagittis ultrices mattis, pretium diam curabitur ridiculus fermentum convallis nunc nulla ipsum. Posuere curae natoque imperdiet magna metus mi varius habitant magnis vehicula class aliquet, mollis lobortis primis dapibus tellus dictum fringilla conubia volutpat montes felis. Leo quam adipiscing nulla cras luctus felis semper auctor porta, natoque placerat ut lobortis cubilia finibus pretium pulvinar, suspendisse lectus duis habitasse elementum iaculis ridiculus ligula.
Placerat volutpat velit quam egestas justo aptent tellus purus, himenaeos nibh metus ex tristique sed ac maximus hac, parturient aliquet fames felis porta dictum turpis. Odio vivamus efficitur rutrum pulvinar bibendum est ex dui hac lectus, morbi euismod blandit tortor in sollicitudin platea senectus ultrices, dictumst quam curabitur scelerisque cras id nascetur elit lorem. Orci ullamcorper euismod nibh erat natoque placerat ante magnis tortor duis dictum ut augue egestas, conubia vitae nunc imperdiet vehicula luctus arcu consequat massa magna venenatis aptent. Aliquet iaculis habitasse penatibus potenti ad efficitur curabitur, convallis senectus rhoncus ullamcorper ante luctus in sem, molestie viverra volutpat nullam magna class. Accumsan turpis est laoreet suscipit sem donec, sodales habitant vestibulum quisque facilisis tempor volutpat, ullamcorper dapibus mattis non rutrum. Cubilia suspendisse ipsum viverra himenaeos massa ligula convallis aenean, placerat efficitur tempus nunc fermentum lobortis habitasse vehicula, nulla tortor nisl mauris arcu gravida neque. Dictum egestas maximus nibh leo himenaeos potenti viverra, lorem pretium sed posuere nascetur varius, fusce non ad sem hac donec.
Fermentum cras vehicula cursus nec auctor augue feugiat est pellentesque venenatis at justo morbi, porttitor tristique sapien habitant posuere vivamus blandit lacinia felis arcu inceptos. Nullam hac dictumst sagittis ultrices tempus libero facilisis rutrum proin, vehicula duis sit tincidunt tempor orci scelerisque at in pharetra, lobortis cras himenaeos blandit platea fermentum phasellus volutpat. Orci interdum metus turpis sodales morbi tellus, sit condimentum in quis vestibulum cursus vivamus, donec sollicitudin duis commodo dignissim.

References

1. Genereux P, Webb JG, SvensonLG, et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am Coll Cardiol. 2012; 60: 1043-1052.

2. Vora AN, Rao SV. Percutaneous or surgical access for transfemoral transcatheter aortic valve implantation. J Thorac Dis. 2018 Nov; 10(Suppl 30): S3595-S3598. doi: 10.21037/jtd.2018.09.48

3. Nakamura M, Chakavarty T, Jilaihami H, et al. Complete percutaneous approach for arterial access in transfemoral transcatheter aortic valve replacement: a comparison with surgical cut-down and closure. Catheter Cardiovasc Interv. 2014; 84: 293-300.

4. Hernandez-Enriquez M, Andrea R, Brugaletta S, et al. Puncture versus surgical cutdown complicaitons of transfemoral aortic valve implantation (from the Spanish TAVI Registry). Am J Cardiol. 2016; 118: 578-84.

5. Scarsini R, De Maria GL, Joseph J, et al. Impact of complications during transfemoral transcatheter aortic valve replacement: how can they be avoided and managed? J Am Heart Assoc. 2019 Sep 17; 8(18): e013801. doi: 10.1161/JAHA.119.013801